Home | News & Events | IDEA News | Early signs that drug 'may delay Alzheimer's decline'

Early signs that drug 'may delay Alzheimer's decline'

idea.nottingham.ac.uk image: test tubes

The first details of how a drug could slow the pace of brain decline for patients with early stage Alzheimer's disease have emerged.

Data from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.

The results, presented to a US conference, are being met with cautious optimism.

Read more on the BBC News website.